In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

The full background on the Goldman Sachs case can be found in our update from earlier this year, but here are the critical facts and issues. In 2010 the stock price of petitioner Goldman Sachs Group, ...

Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs’ claims in this litigation, if ...

In a closely followed case concerning class certification in securities fraud class actions, the U. S. Supreme Court has held that the generic nature of a company’s statements should be considered in ...

Sandoz has announced a number of steps to resolve the US Generic Drug Antitrust Class Action Litigation. Following the previously announced settlements with the U.S. Department of Justice in 2020 and ...

This article first appeared on GuruFocus. A class action lawsuit filed on Friday is bringing Novo Nordisk (NYSE:NVO) back into the spotlight, with allegations that its handling of competition around ...

Add Yahoo as a preferred source to see more of our stories on Google. The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could be ...

Sandoz and its subsidiary Fougera Pharmaceuticals—both indirect subsidiaries of Sandoz Group AG—have entered into a settlement agreement with the class of direct purchaser plaintiffs in the ...